FDA green-lights breast thermography system

The FDA has cleared UE LifeSciences NoTouch BreastScan as an adjunctive diagnostic screening tool for the detection of breast cancer.

NoTouch BreastScan is a computerized functional infrared imaging system with a dual-infrared detector design. It does not require manual interpretation of thermal data; instead, it analyzes temperature pixels from various infrared frames to create a report.

The Philadelphia-based developer of breast cancer detection systems plans to offer NoTouch BreastScan services to gynecology, medical oncology and radiology clinics in the U.S. starting in the New York, New Jersey and Pennsylvania regions.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.